Data Exclusivity under the EU's New Pharmaceutical Legislation

摘要

European data exclusivity rules for pharmaceutical products determine, in part, when generic versions of innovative products can reach the market and start pushing prices down. Both the pharmaceutical industry and national authorities have a major financial and political stake in this regime and it is no surprise that it has formed the arena for extensive legal and political debates.